vs
Orion Properties Inc.（ONL）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Orion Properties Inc.的季度营收约是REGENXBIO Inc.的1.2倍（$35.2M vs $30.3M），Orion Properties Inc.净利率更高（-101.7% vs -221.3%，领先119.7%），REGENXBIO Inc.同比增速更快（43.0% vs -8.2%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -13.6%）
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
ONL vs RGNX — 直观对比
营收规模更大
ONL
是对方的1.2倍
$30.3M
营收增速更快
RGNX
高出51.2%
-8.2%
净利率更高
ONL
高出119.7%
-221.3%
两年增速更快
RGNX
近两年复合增速
-13.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $35.2M | $30.3M |
| 净利润 | $-35.8M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | -101.5% | -190.0% |
| 净利率 | -101.7% | -221.3% |
| 营收同比 | -8.2% | 43.0% |
| 净利润同比 | -9.3% | -31.2% |
| 每股收益（稀释后） | $-0.63 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ONLRGNX
| Q4 25 | $35.2M | $30.3M | ||
| Q3 25 | $37.1M | $29.7M | ||
| Q2 25 | $37.3M | $21.4M | ||
| Q1 25 | $38.0M | $89.0M | ||
| Q4 24 | $38.4M | $21.2M | ||
| Q3 24 | $39.2M | $24.2M | ||
| Q2 24 | $40.1M | $22.3M | ||
| Q1 24 | $47.2M | $15.6M |
净利润ONLRGNX
| Q4 25 | $-35.8M | $-67.1M | ||
| Q3 25 | $-69.0M | $-61.9M | ||
| Q2 25 | $-25.1M | $-70.9M | ||
| Q1 25 | $-9.4M | $6.1M | ||
| Q4 24 | $-32.8M | $-51.2M | ||
| Q3 24 | $-10.2M | $-59.6M | ||
| Q2 24 | $-33.8M | $-53.0M | ||
| Q1 24 | $-26.2M | $-63.3M |
毛利率ONLRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率ONLRGNX
| Q4 25 | -101.5% | -190.0% | ||
| Q3 25 | -185.8% | -176.3% | ||
| Q2 25 | -67.1% | -296.3% | ||
| Q1 25 | -24.4% | 13.6% | ||
| Q4 24 | -85.4% | -242.1% | ||
| Q3 24 | -25.9% | -256.6% | ||
| Q2 24 | -84.1% | -251.3% | ||
| Q1 24 | -55.4% | -408.8% |
净利率ONLRGNX
| Q4 25 | -101.7% | -221.3% | ||
| Q3 25 | -186.0% | -208.3% | ||
| Q2 25 | -67.3% | -331.8% | ||
| Q1 25 | -24.6% | 6.8% | ||
| Q4 24 | -85.4% | -241.3% | ||
| Q3 24 | -26.1% | -246.3% | ||
| Q2 24 | -84.2% | -237.7% | ||
| Q1 24 | -55.6% | -405.4% |
每股收益（稀释后）ONLRGNX
| Q4 25 | $-0.63 | $-1.30 | ||
| Q3 25 | $-1.23 | $-1.20 | ||
| Q2 25 | $-0.45 | $-1.38 | ||
| Q1 25 | $-0.17 | $0.12 | ||
| Q4 24 | $-0.59 | $-0.99 | ||
| Q3 24 | $-0.18 | $-1.17 | ||
| Q2 24 | $-0.60 | $-1.05 | ||
| Q1 24 | $-0.47 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $22.4M | $230.1M |
| 总债务越低越好 | $465.0M | — |
| 股东权益账面价值 | $623.2M | $102.7M |
| 总资产 | $1.2B | $453.0M |
| 负债/权益比越低杠杆越低 | 0.75× | — |
8季度趋势，按日历期对齐
现金及短期投资ONLRGNX
| Q4 25 | $22.4M | $230.1M | ||
| Q3 25 | $32.6M | $274.2M | ||
| Q2 25 | $17.4M | $323.3M | ||
| Q1 25 | $9.4M | $267.9M | ||
| Q4 24 | $15.6M | $234.7M | ||
| Q3 24 | $16.6M | $255.5M | ||
| Q2 24 | $24.2M | $290.4M | ||
| Q1 24 | $23.6M | $338.7M |
总债务ONLRGNX
| Q4 25 | $465.0M | — | ||
| Q3 25 | $483.0M | — | ||
| Q2 25 | $483.0M | — | ||
| Q1 25 | $505.0M | — | ||
| Q4 24 | $492.0M | — | ||
| Q3 24 | $485.0M | — | ||
| Q2 24 | $462.0M | — | ||
| Q1 24 | $471.0M | — |
股东权益ONLRGNX
| Q4 25 | $623.2M | $102.7M | ||
| Q3 25 | $658.8M | $161.5M | ||
| Q2 25 | $728.0M | $213.7M | ||
| Q1 25 | $753.5M | $274.2M | ||
| Q4 24 | $763.9M | $259.7M | ||
| Q3 24 | $800.9M | $301.4M | ||
| Q2 24 | $816.1M | $348.3M | ||
| Q1 24 | $854.6M | $390.7M |
总资产ONLRGNX
| Q4 25 | $1.2B | $453.0M | ||
| Q3 25 | $1.2B | $525.2M | ||
| Q2 25 | $1.3B | $581.0M | ||
| Q1 25 | $1.3B | $490.9M | ||
| Q4 24 | $1.3B | $466.0M | ||
| Q3 24 | $1.4B | $519.1M | ||
| Q2 24 | $1.3B | $569.4M | ||
| Q1 24 | $1.4B | $629.2M |
负债/权益比ONLRGNX
| Q4 25 | 0.75× | — | ||
| Q3 25 | 0.73× | — | ||
| Q2 25 | 0.66× | — | ||
| Q1 25 | 0.67× | — | ||
| Q4 24 | 0.64× | — | ||
| Q3 24 | 0.61× | — | ||
| Q2 24 | 0.57× | — | ||
| Q1 24 | 0.55× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $23.6M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流ONLRGNX
| Q4 25 | $23.6M | $-52.3M | ||
| Q3 25 | $5.7M | $-56.0M | ||
| Q2 25 | $11.6M | $-49.3M | ||
| Q1 25 | $-2.2M | $33.6M | ||
| Q4 24 | $54.3M | $-31.6M | ||
| Q3 24 | $13.8M | $-40.5M | ||
| Q2 24 | $17.0M | $-45.5M | ||
| Q1 24 | $11.0M | $-55.5M |
自由现金流ONLRGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率ONLRGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度ONLRGNX
| Q4 25 | — | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率ONLRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ONL
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
